Cancer cells bypass cell-cycle checkpoints and anti-proliferative programmes enforced by tumor-suppressor proteins. Canonical failures: RB inactivation (by CDKN2A/p16 loss, CDK4/6 hyperactivation, or direct mutation) frees E2F-driven…
Cancer cells bypass cell-cycle checkpoints and anti-proliferative programmes enforced by tumor-suppressor proteins. Canonical failures: RB inactivation (by CDKN2A/p16 loss, CDK4/6 hyperactivation, or direct mutation) frees E2F-driven…